Campylobacter jejuni lipooligosaccharides modulate dendritic cell-mediated T cell polarization in a sialic acid linkage-dependent manner

Infection and Immunity

Volumn 79, Issue 7, 2011, Pages 2681-2689

  Bax, Marieke ^a,d   Kuijf, Mark L ^b   Heikema, Astrid P ^b   van Rijs, Wouter ^b   Bruijns, Sven C M ^a   García Vallejo, Juan J ^a   Crocker, Paul R ^c   Jacobs, Bart C ^b   van Vliet, Sandra J ^a   van Kooyk, Yvette ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD86 ANTIGEN; GAMMA INTERFERON; GANGLIOSIDE; GANGLIOSIDE GB16; GANGLIOSIDE GD 1A; GANGLIOSIDE GM1; INTERLEUKIN 12; INTERLEUKIN 4; LIPOOLIGOSACCHARIDE; OX40 LIGAND; SIALIC ACID; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ARTICLE; CAMPYLOBACTER JEJUNI; CELL DIFFERENTIATION; CELL MATURATION; CYTOKINE PRODUCTION; DENDRITIC CELL; GUILLAIN BARRE SYNDROME; HUMAN; HUMAN CELL; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH1 CELL; TH2 CELL;

CAMPYLOBACTER JEJUNI; CARBOHYDRATE CONFORMATION; CELL DIFFERENTIATION; CELL LINE; CELL POLARITY; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; G(M1) GANGLIOSIDE; GANGLIOSIDES; GUILLAIN-BARRE SYNDROME; HEK293 CELLS; HUMANS; INTERLEUKIN-12; LECTINS; LIPOPOLYSACCHARIDES; MOLECULAR MIMICRY; N-ACETYLNEURAMINIC ACID; OX40 LIGAND; POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; TH1 CELLS; TH2 CELLS;

EID: 79959431648     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00009-11     Document Type: Article

References (51)

1. Al-Sayeqh, A. F., M. F. Loughlin, E. Dillon, K. H. Mellits, and I. F. Connerton. 2010. Campylobacter jejuni activates NF-kappaB independently of TLR2, TLR4, Nod1 and Nod2 receptors. Microb. Pathog. 49:294-304.
2. Ang, C. W., B. C. Jacobs, and J. D. Laman. 2004. The Guillain-Barre syndrome: a true case of molecular mimicry. Trends Immunol. 25:61-66.
3. Angata, T., and E. Brinkman-Van der Linden. 2002. I-type lectins. Biochim. Biophys. Acta 1572:294-316.
4. Angata, T., and A. Varki. 2002. Chemical diversity in the sialic acids and related alpha-keto acids: an evolutionary perspective. Chem. Rev. 102:439-469.
5. Avril, T., H. Floyd, F. Lopez, E. Vivier, and P. R. Crocker. 2004. The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by Siglecs-7 and -9, CD33-related Siglecs expressed on human monocytes and NK cells. J. Immunol. 173:6841-6849.
6. Avril, T., E. R. Wagner, H. J. Willison, and P. R. Crocker. 2006. Sialic acid-binding immunoglobulin-like lectin 7 mediates selective recognition of sialylated glycans expressed on Campylobacter jejuni lipooligosaccharides. Infect. Immun. 74:4133-4141.
7. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392:245-252.
8. Bax, M., et al. 2007. Dendritic cell maturation results in pronounced changes in glycan expression affecting recognition by siglecs and galectins. J. Immunol. 179:8216-8224.
9. Bax, M., S. J. van Vliet, M. Litjens, J. J. Garcia-Vallejo, and Y. van Kooyk. 2009. Interaction of polysialic acid with CCL21 regulates the migratory capacity of human dendritic cells. PLoS One 4:e6987.
10. Carlin, A. F., A. L. Lewis, A. Varki, and V. Nizet. 2007. Group B streptococcal capsular sialic acids interact with siglecs (immunoglobulin-like lectins) on human leukocytes. J. Bacteriol. 189:1231-1237.
11. Corfield, T. 1992. Bacterial sialidases-roles in pathogenicity and nutrition. Glycobiology 2:509-521.
12. Crocker, P. R., J. C. Paulson, and A. Varki. 2007. Siglecs and their roles in the immune system. Nat. Rev. Immunol. 7:255-266.
13. Crocker, P. R., and P. Redelinghuys. 2008. Siglecs as positive and negative regulators of the immune system. Biochem. Soc. Trans. 36:1467-1471.
14. de Jong, E. C., et al. 2002. Microbial compounds selectively induce Th1 cell-promoting or Th2 cell-promoting dendritic cells in vitro with diverse Th cell-polarizing signals. J. Immunol. 168:1704-1709.
15. Garcia-Vallejo, J. J., et al. 2004. Approach for defining endogenous reference genes in gene expression experiments. Anal. Biochem. 329:293-299.
16. Gilbert, M., et al. 2000. Biosynthesis of ganglioside mimics in Campylobacter jejuni OH4384. Identification of the glycosyltransferase genes, enzymatic synthesis of model compounds, and characterization of nanomole amounts by 600-mhz (1)h and (13)c NMR analysis. J. Biol. Chem. 275:3896-3906.
17. Godschalk, P. C., et al. 2004. The crucial role of Campylobacter jejuni genes in anti-ganglioside antibody induction in Guillain-Barre syndrome. J. Clin. Invest. 114:1659-1665.
18. Godschalk, P. C., et al. 2007. Structural characterization of Campylobacter jejuni lipooligosaccharide outer cores associated with Guillain-Barre and Miller Fisher syndromes. Infect. Immun. 75:1245-1254.
19. Hargreaves, D. C., and R. Medzhitov. 2005. Innate sensors of microbial infection. J. Clin. Immunol. 25:503-510.
20. Hartnell, A., et al. 2001. Characterization of human sialoadhesin, a sialic acid binding receptor expressed by resident and inflammatory macrophage populations. Blood 97:288-296.
21. Heikema, A. P., et al. 2010. Characterization of the specific interaction between sialoadhesin and sialylated Campylobacter jejuni lipooligosaccharides. Infect. Immun. 78:3237-3246.
22. Hu, L., M. D. Bray, M. Osorio, and D. J. Kopecko. 2006. Campylobacter jejuni induces maturation and cytokine production in human dendritic cells. Infect. Immun. 74:2697-2705.
23. Hudson, S. A., N. V. Bovin, R. L. Schnaar, P. R. Crocker, and B. S. Bochner. 2009. Eosinophil-selective binding and proapoptotic effect in vitro of a synthetic Siglec-8 ligand, polymeric 6α-sulfated sialyl Lewis x. J. Pharmacol. Exp. Ther. 330:608-612.
24. Jacobs, B. C., M. P. Hazenberg, P. A. van Doorn, H. P. Endtz, and F. G. van der Meche. 1997. Cross-reactive antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in patients with Guillain-Barre or Miller Fi.0sh0er syndrome. J. Infect. Dis. 175:729-733.
25. Jacobs, B. C., et al. 1996. Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barre syndrome. Ann. Neurol. 40:181-187.
26. Jones, C., M. Virji, and P. R. Crocker. 2003. Recognition of sialylated meningococcal lipopolysaccharide by siglecs expressed on myeloid cells leads to enhanced bacterial uptake. Mol. Microbiol. 49:1213-1225.
27. Kelm, S., and R. Schauer. 1997. Sialic acids in molecular and cellular interactions. Int. Rev. Cytol. 175:137-240.
28. Kirchberger, S., et al. 2005. Human rhinoviruses inhibit the accessory function of dendritic cells by inducing sialoadhesin and B7-H1 expression. J. Immunol. 175:1145-1152.
29. Koga, M., M. Takahashi, M. Masuda, K. Hirata, and N. Yuki. 2005. Campylobacter gene polymorphism as a determinant of clinical features of Guillain-Barre syndrome. Neurology 65:1376-1381.
30. Kuijf, M. L., et al. 2010. TLR4-mediated sensing of Campylobacter jejuni by dendritic cells is determined by sialylation. J. Immunol. 185:748-755.
31. Latz, E., et al. 2002. Lipopolysaccharide rapidly traffics to and from the Golgi apparatus with the Toll-like receptor 4-MD-2-CD14 complex in a process that is distinct from the initiation of signal transduction. J. Biol. Chem. 277:47834-47843.
32. Lock, K., J. Zhang, J. Lu, S. H. Lee, and P. R. Crocker. 2004. Expression of CD33-related siglecs on human mononuclear phagocytes, monocyte-derived dendritic cells and plasmacytoid dendritic cells. Immunobiology. 209:199-207.
33. McMillan, S. J., and P. R. Crocker. 2008. CD33-related sialic-acid-binding immunoglobulin-like lectins in health and disease. Carbohydr. Res. 343: 2050-2056.
34. Mosmann, T. R., and R. L. Coffman. 1989. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:145-173.
35. Nicoll, G., et al. 1999. Identification and characterization of a novel siglec, siglec-7, expressed by human natural killer cells and monocytes. J. Biol. Chem. 274:34089-34095.
36. O'Reilly, M. K., and J. C. Paulson. 2009. Siglecs as targets for therapy in immune-cell-mediated disease. Trends Pharmacol. Sci. 30:240-248.
37. Rapoport, E., I. Mikhalyov, J. Zhang, P. Crocker, and N. Bovin. 2003. Ganglioside binding pattern of CD33-related siglecs. Bioorg. Med. Chem. Lett. 13:675-678.
38. Rathinam, V. A., D. M. Appledorn, K. A. Hoag, A. Amalfitano, and L. S. Mansfield. 2009. Campylobacter jejuni-induced activation of dendritic cells involves cooperative signaling through Toll-like receptor 4 (TLR4)-MyD88 and TLR4-TRIF axes. Infect. Immun. 77:2499-2507.
39. Rathinam, V. A., K. A. Hoag, and L. S. Mansfield. 2008. Dendritic cells from C57BL/6 mice undergo activation and induce Th1-effector cell responses against Campylobacter jejuni. Microbes Infect. 10:1316-1324.
40. Razi, N., and A. Varki. 1999. Cryptic sialic acid binding lectins on human blood leukocytes can be unmasked by sialidase treatment or cellular activation. Glycobiology 9:1225-1234.
41. Reis e Sousa, C. 2004. Toll-like receptors and dendritic cells: for whom the bug tolls. Semin. Immunol. 16:27-34.
42. Reis e Sousa, C. 2006. Dendritic cells in a mature age. Nat. Rev. Immunol. 6:476-483.
43. Sallusto, F., and A. Lanzavecchia. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179:1109-1118.
44. Snijders, A., et al. 1996. Regulation of bioactive IL-12 production in lipo-polysaccharide-stimulated human monocytes is determined by the expression of the p35 subunit. J. Immunol. 156:1207-1212.
45. Trent, M. S., C. M. Stead, A. X. Tran, and J. V. Hankins. 2006. Diversity of endotoxin and its impact on pathogenesis. J. Endotoxin Res. 12:205-223.
46. Van Belkum, A., et al. 2001. A Campylobacter jejuni gene associated with immune-mediated neuropathy. Nat. Med. 7:752-753.
47. van Vliet, S. J., J. J. Garcia-Vallejo, and Y. van Kooyk. 2008. Dendritic cells and C-type lectin receptors: coupling innate to adaptive immune responses. Immunol. Cell Biol. 86:580-587.
48. Varki, A., and T. Angata. 2006. Siglecs-the major subfamily of I-type lectins. Glycobiology 16:1R-27R.
49. Yamaji, T., T. Teranishi, M. S. Alphey, P. R. Crocker, and Y. Hashimoto. 2002. A small region of the natural killer cell receptor, Siglec-7, is responsible for its preferred binding to alpha 2,8-disialyl and branched alpha 2,6-sialyl residues. A comparison with Siglec-9. J. Biol. Chem. 277:6324-6332.
50. York, M. R., et al. 2007. A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and Toll-like receptor agonists. Arthritis Rheum. 56:1010-1020.
51. Zhu, J., and W. E. Paul. 2008. CD4 T cells: fates, functions, and faults. Blood 112:1557-1569.